You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tissue mesothelin

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clinical Management of Esophageal Adenocarcinoma (EAC)

Active, not recruiting
  • Esophageal Cancer
  • Adenocarcinoma
  • serum and tissue mesothelin
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 1, 2021

Study of Patients With Malignant Mesothelioma

Recruiting
  • Mesothelioma
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 7, 2022

    Pleural Malignant Mesothelioma Trial in Canada, United States (Anetumab Ravtansine, Laboratory Biomarker Analysis,

    Active, not recruiting
    • Pleural Malignant Mesothelioma
    • Anetumab Ravtansine
    • +3 more
    • Birmingham, Alabama
    • +32 more
    Dec 24, 2022

    Mesothelioma Trial run by the National Cancer Institute (NCI) (LMB-100, nab-paclitaxel)

    Completed
    Has Results
    • Mesothelioma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 28, 2022

    Tumors With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic Trial run by the NCI (LMB-100,

    Active, not recruiting
    Has Results
    • Neoplasms With Mesothelin Expression
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 18, 2022

    Tumors, Pancreatic Tumors Trial run by the NCI (LMB-100, Nab-Paclitaxel, Mesothelin Expression)

    Completed
    Has Results
    • Neoplasms
    • Pancreatic Neoplasms
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 16, 2022

    Pancreatic Cancer Trial in New Haven, New Brunswick, Nashville (anetumab ravtansine)

    Completed
    Has Results
    • Pancreatic Cancer
    • anetumab ravtansine
    • New Haven, Connecticut
    • +2 more
    Oct 11, 2021

    Oncology Trial in United States (BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg))

    Completed
    • Oncology
    • New Haven, Connecticut
    • +7 more
    Jul 6, 2021

    Mesothelioma Trial run by the NCI (LMB-100, Pembrolizumab)

    Terminated
    Has Results
    • Mesothelioma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Nov 3, 2021

    Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

    Active, not recruiting
    • Fallopian Tube Endometrioid Adenocarcinoma
    • +7 more
    • Anetumab Ravtansine
    • +2 more
    • Orange, California
    • +22 more
    Oct 22, 2022

    Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

    Not yet recruiting
    • Mesothelin-positive Advanced Malignant Solid Tumors
    • Anti-mesothelin CAR-T cells
    • (no location specified)
    Mar 13, 2023

    Mesothelin-positive Advanced Malignant Solid Tumors Trial in Hangzhou (UCLM802 Cell Injection (Anti-mesothelin CAR-T cells))

    Recruiting
    • Mesothelin-positive Advanced Malignant Solid Tumors
    • UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital Zhejiang University School of Medi
    May 11, 2023

    Solid Tumor Trial (UCLM802 Cell Injection)

    Not yet recruiting
    • Solid Tumor
    • UCLM802 Cell Injection
    • (no location specified)
    Mar 7, 2023

    Spread of Colorectal Carcinomatosis

    Completed
    • Peritoneal Carcinomatosis
    • Sampling peritoneal tissue
    • Ghent, Belgium
      Ghent University Hospital
    Dec 9, 2022

    Pancreas Cancer, CAR-T Cell Therapy, Mesothelin Trial in Guangzhou (CAR-T cells)

    Recruiting
    • Pancreas Cancer
    • +3 more
    • CAR-T cells
    • Guangzhou, Guangdong, China
      The Second Affiliated Hospital of Guangzhou Medical University
    Mar 10, 2023

    Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific

    Recruiting
    • Metastatic Pancreatic Ductal Adenocarcinoma
    • Stage IV Pancreatic Cancer AJCC v8
    • Autologous Mesothelin-specific TCR-T Cells
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 31, 2023

    Ovarian Cancer Trial in Hangzhou (mesothelin-specific chimeric antigen receptor T cell injection)

    Recruiting
    • Ovarian Cancer
    • mesothelin-specific chimeric antigen receptor T cell injection
    • Hangzhou, China
      First affiliated hospital, School of Medicine, Zhejiang Universi
    May 12, 2022

    Hairy Cell and Other Leukemias, and to Develop Recombinant

    Recruiting
    • Hairy Cell Leukemia (HCL)
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Aug 24, 2022

      Mesothelin Positive, Stage III NSCLC AJCC v7, Stage IIIA NSCLC AJCC v7 Trial in Phoenix, Jacksonville, Rochester (Anetumab

      Terminated
      Has Results
      • Mesothelin Positive
      • +4 more
      • Anetumab Ravtansine
      • +2 more
      • Phoenix, Arizona
      • +2 more
      Jan 5, 2023

      Peritoneal Malignant Mesothelioma Trial in United States (biological, drug, procedure)

      Recruiting
      • Peritoneal Malignant Mesothelioma
      • Atezolizumab
      • +8 more
      • Phoenix, Arizona
      • +25 more
      Feb 2, 2023

      Advanced Cancers Associated With Mesothelin Expression Trial in United States (HPN536)

      Active, not recruiting
      • Advanced Cancers Associated With Mesothelin Expression
      • HPN536
      • Phoenix, Arizona
      • +15 more
      Sep 9, 2022

      Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant Trial (SynKIR-110, Autologous T cells Transduced with

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
      • SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
      • (no location specified)
      Oct 5, 2022

      Solid Tumor Trial in Shanghai (aPD1-MSLN-CAR T cells)

      Recruiting
      • Solid Tumor
      • αPD1-MSLN-CAR T cells
      • Shanghai, Shanghai, China
        Shanghai Mengchao Cancer Hospital
      Oct 24, 2022

      Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,

      Recruiting
      • Advanced or Metastatic Solid Tumors
      • CD40 ligand expressing MSLN-CAR T cells
      • +2 more
      • Beijing, Beijing, China
        Kaichao Feng
      Jan 19, 2023

      Solid Tumor, Adult, Colorectal Cancer, NSCLC Trial in United States (A2B694, xT CDx with HLA-LOH Assay)

      Not yet recruiting
      • Solid Tumor, Adult
      • +19 more
      • A2B694
      • xT CDx with HLA-LOH Assay
      • Duarte, California
      • +9 more
      Sep 22, 2023